E-[6-(3-amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine | 383432-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: E-[6-(3-amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine
• 英文别名: (E)-6-(3-Aminoprop-1-en-1-yl)-N-(3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)quinazolin-4-amine；6-[(E)-3-aminoprop-1-enyl]-N-[3-methyl-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine
• CAS: 383432-26-6
• 化学式: C₂₄H₂₃N₅O
• 分子量: 397.48
• InChiKey: KTGLGIUGHIGVMU-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  86
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  E-[6-(3-amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine 在 甲醇 、 水 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 E-2-Hydroxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-isobutyramide
  参考文献：
  名称：

  WO2006/129163

  摘要：

  公开号：

文献信息

• [EN] PROCESSES FOR THE PREPARATION OF N-((((PYRIDINYLOXY) -PHENYLAMINO) QUINAZOLINYL)- ALLYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS WELL AS INTERMEDIATES OF SUCH PROCESSES AND PROCESSES FOR THE PREPARATION OF SUCH INTERMEDIATES<br/>[FR] PROCEDES DE PREPARATION DE DERIVES DE N-((((PYRIDINYLOXY) -PHENYLAMINO) QUINAZOLINYL)- ALLYL) ACETAMIDE ET DES COMPOSES APPARENTES ET INTERMEDIAIRES POUR CES PROCEDES ET PROCEDES DE PREPARATION DE CES INTERMEDIAIRES
  申请人：PFIZER PROD INC

  公开号：WO2004089934A1

  公开（公告）日：2004-10-21

  The invention relates to processes for preparing compounds of the formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R6 R11, R13 R14 R15, R16, R17, k, I, and m are as defined herein. The present invention also relates to intermediates represented by the formula (3a) wherin R4, and R5 are independently selected from hydrogen and C1-C6 alkyl; each R13, R14, R15 and R16 is independently selected from hydrogen, C1-C6 alkyl and CH2OH, R17 and R18 are independently C1-C6 alkyl, and k and I are independently an integer from 1 to 3, as well as to a process for preparing these intermediates.

  本发明涉及制备式（1）化合物的方法，以及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R6、R11、R13、R14、R15、R16、R17、k、I和m的定义如本文所述。本发明还涉及由式（3a）表示的中间体，其中R4和R5分别独立地选择氢和C1-C6烷基；每个R13、R14、R15和R16独立地选择氢、C1-C6烷基和CH2OH，R17和R18分别独立地选择C1-C6烷基，k和I独立地选择1至3之间的整数，以及制备这些中间体的方法。
• Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
  申请人：Connell D. Richard

  公开号：US20050101618A1

  公开（公告）日：2005-05-12

  This invention relates to a method of treatment of cancer with a combination of an erbB2 ligand and an antibody, in mammals. More particularly, this invention relates to a method of treating cancer by administering an erbB2 ligand in combination with an erbB antibody. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

  本发明涉及一种在哺乳动物中使用erbB2配体和抗体的组合治疗癌症的方法。更具体地，本发明涉及通过联合给予erbB2配体和erbB抗体来治疗癌症的方法。本发明还涉及一种在哺乳动物，特别是人类中治疗异常细胞生长的有用工具包。
• Substituted bicyclic derivatives for the treatment of abnormal cell growth
  申请人：——

  公开号：US20020169165A1

  公开（公告）日：2002-11-14

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 3 , R 4 , R 5 , R 11 , m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  该发明涉及公式11的化合物，以及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R5、R11、m和p如本文所定义。该发明还涉及通过给予公式1的化合物治疗哺乳动物的异常细胞增长的方法，并且涉及用含有公式1的化合物的制药组合物治疗这种疾病的方法。该发明还涉及制备公式1的化合物的方法。
• Small molecules for the treatment of abnormal cell growth
  申请人：Pfizer Inc.

  公开号：US20030171386A1

  公开（公告）日：2003-09-11

  This invention relates to small molecules that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such small molecules in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds. The invention further relates to small molecules that are selective for erbB2 receptor over the erbB1 receptor, wherein said erbB2 inhibitor has a range of selectivities for erbB2 over erbB1 between 50-1500.

  本发明涉及小分子化合物，可用于治疗哺乳动物中的异常细胞生长，如癌症。本发明还涉及使用这些小分子化合物治疗哺乳动物中的异常细胞生长的方法，特别是人类，并涉及含有这些化合物的制药组合物。本发明进一步涉及选择性针对erbB2受体而非erbB1受体的小分子化合物，其中所述erbB2抑制剂对erbB2与erbB1的选择性范围在50-1500之间。
• Processes for the preparation of substituted bicyclic derivatives
  申请人：Ripin H. B. David

  公开号：US20050026940A1

  公开（公告）日：2005-02-03

  The invention relates to processes for preparing compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 3 , R 4 , R 6 , R 11 , R 13 , R 14 , R 15 , R 16 , R 17 , k, l, and m are as defined herein. The compounds of formula 1 are useful intermediates toward preparing compounds that may be used in treating abnormal cell growth in mammals by administering pharmaceutical compositions.

  本发明涉及制备式1化合物的过程，以及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R6、R11、R13、R14、R15、R16、R17、k、l和m的定义如本文所述。式1化合物是制备可用于治疗哺乳动物异常细胞生长的化合物的有用中间体，通过给药药物组合物。